AlphAIAlphAI — Financial news for AI agents
seekingalpha.comSEP 11 min read$TEM

Tempus AI stock upgraded at Piper Sandler (TEM:NASDAQ)

Piper Sandler upgraded Tempus AI (TEM) to Overweight, raising its price target to $76 from $56. Analyst David Westenberg cited three key growth drivers for the AI-driven diagnostics company.

Original reporting
seekingalpha.com
Published Sep 1, 2026, 3:49 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 1, 2026, 4:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$TEM
Bullish
medium confidence
Mentioned
$TEM · $PIPR
Relevance
7/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$TEMBullishHigh
01

Why it matters

Analyst upgrade could attract new buying interest and lift the stock toward the new $76 target.

02

Market read

The upgrade adds a bullish catalyst for TEM, potentially influencing related AI‑health stocks.

03

What to watch

Execution risk of AI diagnostics rollout not detailed.

Relevance 7/10Novelty 7/10Timing: today

Background

Tempus AI is an AI‑driven diagnostics company listed on NASDAQ.

Company-level read

Ticker impact

$TEMBullishMedium confidence
Context

Piper Sandler upgraded Tempus AI to Overweight and raised its price target to $76 from $56.

Expected impact

Potential price increase toward new target.

Evidence & confidence

Upgrade and higher target reflect improved growth outlook.

Market effects

Sector

May boost sentiment for AI‑driven diagnostics sector.

Regional

Limited to US biotech/AI equities.

Global

Minor global impact.

Counterpoint

What could challenge this read

Upgrade could be premature if growth drivers falter.

Key entities

  • Analyst Firm
    Piper Sandler

    Provided the upgrade and new price target.

Read at source← All news

Also covered by

2 outlets

Related articles

SEP 17
$TEMMedAI 8/10

TEM Stock Jumps As Tempus AI Joins Profitable AI Health Elite

Tempus AI Inc. (NASDAQ: TEM) shares rose 14.38% on September 17, 2026, driven by strong Q2 2026 results. Revenue grew 22% YoY to $382.5M, with net income and EBITDA turning positive at $5.6M and $45M, respectively. Gross margin is 73.5%. The company plans to acquire Personalis, funded by $816M in cash and investments, despite $1.36B in long-term debt. TEM's stock has surged from $62 to $80, attracting momentum traders.

timothysykes.com3 min
SEP 17
$TEMMed

Tempus AI Is Ripping 30% Higher This Week After Morgan Stanley Boosts Revenue Outlook

Tempus AI (TEM) shares surged 29.98% this week after Morgan Stanley highlighted new reimbursement-driven revenue growth. CEO Eric Lefkofsky estimated xT pricing could add $80M-$100M in 2025, and xF approval $250M-$300M annually. Q2 revenue was $382.49M, up 21.6% YoY, with full-year guidance raised to $1.595B-$1.605B. Analysts revised FY2027 EPS estimates positively, with a consensus revenue estimate of $1.97B.

247wallst.com2 min
SEP 15
$TEMHighAI 8/10

Tempus AI (TEM) Jumps As Upgrade, Acquisition Fuel Bullish Momentum

Tempus AI Inc. (TEM) shares rose 6.62% after Piper Sandler upgraded it to Overweight with a $76 price target. The company reported Q2 2026 revenue of $382.5M, up 22% YoY, and turned profitable. TEM is acquiring Personalis for $1.5B to expand its tumor-sequencing platform. The stock trades near $66.33, with strong cash position and improving margins.

stockstotrade.com3 min